Department of Paediatrics, Medical Centre Leeuwarden, P.O. Box 888, 8901 BR Leeuwarden, The Netherlands.
Respir Med. 2009 Aug;103(8):1167-73. doi: 10.1016/j.rmed.2009.02.010. Epub 2009 Mar 9.
Recent developments concerning pressurized metered dose inhalers (pMDIs) with inhaled corticosteroids (ICS) are the introduction of ciclesonide and the replacement of propellants. As the results of in vivo studies depend on pMDIperformance, it is necessary to evaluate pMDIs in vitro for delivered dose and particle size distributions under different conditions.
Fluticasone 125microg, budesonide 200microg, beclomethasone HFA100microg, and ciclesonide 160microg were compared for delivered dose and particle size using laser diffraction analysis with inspiratory flow rates of 10, 20 and 30l/s.
The volume median diameter of budesonide was 3.5microm, fluticasone 2.8microm, beclomethasone and ciclesonide both 1.9microm. The mouthpiece retention was up to 30% of the nominal dose for beclomethasone and ciclesonide, 11-19% for the other pMDIs. Lifespan, flow rate, and air humidity had no significant influence on particle size distribution. The delivered dose of beclomethasone, budesonide, and ciclesonide remained constant over the lifespan. The delivered dose of fluticasone 125 decreased from 106% to 63%; fluticasone 250 also decreased whereas fluticasone 50 remained constant.
There is a significant difference in median particle size distribution between the different ICS pMDIs. Air humidity and inspiratory flow rate have no significant influence on particle size distribution. Ciclesonide 160 and beclomethasone 100 deliver the largest fine particle fractions of 1.1-3.1microm. The changes in delivered dose during the lifespan for the fluticasone 125 and 250 may have implications for patient care.
最近有关装有吸入性皮质类固醇(ICS)的加压定量吸入器(pMDI)的发展包括昔萘酸氯地米松的引入和推进剂的更换。由于体内研究的结果取决于 pMDI 的性能,因此有必要在不同条件下对 pMDI 进行体外评估,以确定输送剂量和颗粒分布。
比较了氟替卡松 125μg、布地奈德 200μg、丙酸倍氯米松 HFA100μg 和昔萘酸氯地米松 160μg 的输送剂量和粒径,使用激光衍射分析,吸气流速分别为 10、20 和 30l/s。
布地奈德的体积中位直径为 3.5μm,氟替卡松为 2.8μm,丙酸倍氯米松和昔萘酸氯地米松均为 1.9μm。对于丙酸倍氯米松和昔萘酸氯地米松,口含器的保留量高达名义剂量的 30%,其他 pMDI 则为 11-19%。使用寿命、流速和空气湿度对粒径分布没有显著影响。丙酸倍氯米松、布地奈德和昔萘酸氯地米松的输送剂量在使用寿命内保持不变。氟替卡松 125 的输送剂量从 106%降至 63%;氟替卡松 250 也减少了,而氟替卡松 50 则保持不变。
不同 ICS pMDI 的中值粒径分布存在显著差异。空气湿度和吸气流速对粒径分布没有显著影响。昔萘酸氯地米松 160 和丙酸倍氯米松 100 输送 1.1-3.1μm 的细颗粒分数最大。氟替卡松 125 和 250 在使用寿命内输送剂量的变化可能对患者护理产生影响。